C J Witton1, S J K Hawe, T G Cooke, J M S Bartlett. 1. Endocrine Cancer Group, Division of Cancer Sciences and Molecular Pathology, University Department of Surgery, Glasgow Royal Infirmary, Glasgow, UK.
Abstract
AIMS: Inflammation and hormonal signalling induce cyclooxygenase 2 (COX2) expression in solid tumours. COX2 expression is linked to neovascularization and tumour growth. HER2 modulates colorectal cancer COX2 expression. We investigated interactions between COX2 and HER1-4 in breast cancer. METHODS AND RESULTS: COX2 expression was localized to epithelial cells with 21.2% of cases expressing higher levels than normal epithelium. Elevated COX2 expression was not associated with size, grade, high Nottingham prognostic index (NPI) or oestrogen receptor (ER) negativity. No association was observed between COX2 and HER1-4 expression. High COX2 expression was associated with reduced disease-free survival (P = 0.03) and disease-related survival in ER-negative (P = 0.046) but not ER-positive disease (P = 0.835). CONCLUSION: HER1, 2, 3 and 4 are not associated with high breast tumour COX2 expression. COX2 is frequently expressed in breast carcinoma cells and adjacent epithelium. COX2 may be an important factor in promoting tumour progression in ER-negative tumours and a potential drug target in breast tumours.
AIMS: Inflammation and hormonal signalling induce cyclooxygenase 2 (COX2) expression in solid tumours. COX2 expression is linked to neovascularization and tumour growth. HER2 modulates colorectal cancerCOX2 expression. We investigated interactions between COX2 and HER1-4 in breast cancer. METHODS AND RESULTS:COX2 expression was localized to epithelial cells with 21.2% of cases expressing higher levels than normal epithelium. Elevated COX2 expression was not associated with size, grade, high Nottingham prognostic index (NPI) or oestrogen receptor (ER) negativity. No association was observed between COX2 and HER1-4 expression. High COX2 expression was associated with reduced disease-free survival (P = 0.03) and disease-related survival in ER-negative (P = 0.046) but not ER-positive disease (P = 0.835). CONCLUSION:HER1, 2, 3 and 4 are not associated with high breast tumourCOX2 expression. COX2 is frequently expressed in breast carcinoma cells and adjacent epithelium. COX2 may be an important factor in promoting tumour progression in ER-negative tumours and a potential drug target in breast tumours.
Authors: Nagehan Ozdemir Barısık; Sevinc Hallac Keser; Aylin Ege Gul; Sibel Sensu; Nilufer Onak Kandemir; Hasan Fehmi Kucuk; Mahmut Gumus; Nimet Karadayı Journal: Med Oncol Date: 2010-03-31 Impact factor: 3.064
Authors: Sara Jonmarker Jaraj; Philippe Camparo; Helen Boyle; François Germain; Bo Nilsson; Fredrik Petersson; Lars Egevad Journal: Virchows Arch Date: 2009-09-18 Impact factor: 4.064
Authors: Michelle D Holmes; Wendy Y Chen; Stuart J Schnitt; Laura Collins; Graham A Colditz; Susan E Hankinson; Rulla M Tamimi Journal: Breast Cancer Res Treat Date: 2011-07-05 Impact factor: 4.872
Authors: P Cejas; M A García-Cabezas; E Casado; J Barriuso; J A Fresno; E Díaz; C Belda-Iniesta; J Castro; E Espinosa; P Zamora; J Feliu; A Redondo; D A Hardisson; M González-Barón Journal: Clin Transl Oncol Date: 2005-07 Impact factor: 3.405
Authors: Kailash Mosalpuria; Carolyn Hall; Savitri Krishnamurthy; Ashutosh Lodhi; D Michael Hallman; Mary S Baraniuk; Anirban Bhattacharyya; Anthony Lucci Journal: Mol Clin Oncol Date: 2014-06-23